Immunosuppressive combination therapy

This page covers all Immunosuppressive combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS), mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid), mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone).

Targets

Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS) · mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid) · mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone) · T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus) · Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine) · Calcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone) · IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF) · IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone) · Calcineurin, mTOR, glucocorticoid receptor · T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)

Marketed (13)

• CsA+MMF+CS · Pfizer · Immunology / Transplantation
  This combination suppresses the immune system through multiple pathways: cyclosporine inhibits T-cell activation, mycophenolate mofetil blocks lymphocyte proliferation, and corticosteroids broadly dampen inflammatory responses.
• Sirolimus+MMF or MPS or AZA+Steroid · Wyeth is now a wholly owned subsidiary of Pfizer · Immunology / Transplantation
  This combination regimen suppresses T-cell proliferation and antibody production through mTOR inhibition (sirolimus) and inosine monophosphate dehydrogenase inhibition (MMF/MPS/AZA), used to prevent organ rejection.
• Everolimus+Tacrolimus+Prednisone · Fundação Pró Rim · Immunology / Transplantation
  This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation.
• ATG+mycophénolate mofétil+tacrolimus · University Hospital, Toulouse · Immunology / Transplantation
  This combination suppresses the immune system through multiple pathways to prevent organ rejection after transplantation.
• Dexamethasone Azathioprine Pulse therapy · Jinnah Postgraduate Medical Centre · Immunology / Rheumatology
  This combination therapy uses dexamethasone (a corticosteroid) to suppress inflammation and azathioprine (an immunosuppressant) to inhibit T-cell proliferation, administered in pulse doses for rapid immune modulation.
• tacrolimus OD, mycophenolic acid, prednisolone · University Medical Center Groningen · Immunology / Transplantation
  This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.
• Cyclophosphamide, Azathioprine,prednisone,methylprednisolone · Assistance Publique - Hôpitaux de Paris · Immunology
  This combination regimen suppresses the immune system through multiple pathways: cyclophosphamide and azathioprine inhibit lymphocyte proliferation, while corticosteroids (prednisone and methylprednisolone) broadly suppress inflammatory and immune responses.
• Kidney transplant maintenance immunosuppression · Imperial College Healthcare NHS Trust · Immunology / Transplantation
  Kidney transplant maintenance immunosuppression regimens suppress the recipient's immune system to prevent rejection of the transplanted organ.
• Basiliximab, Tacrolimus, MMF · University Hospital Freiburg · Immunology / Transplantation
  This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.
• Zenapax®, CellCept® and prednisolone · University of Oslo School of Pharmacy · Immunology / Transplantation
  This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation.
• ATG/PTCy · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Oncology/Hematology
  ATG/PTCy is a combination immunosuppressive regimen that depletes T cells and provides graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.
• CsA+Rapamune+CS · Pfizer · Immunology / Transplantation
  This triple immunosuppressive regimen combines calcineurin inhibition, mTOR inhibition, and corticosteroid activity to prevent organ rejection by suppressing T-cell activation and proliferation.
• Mycophenolate+Tacrolimus+Prednisone · Fundação Pró Rim · Immunology / Transplantation
  This triple immunosuppressive regimen suppresses T-cell proliferation and activation to prevent organ rejection after transplantation.

Phase 3 pipeline (8)

• MMF, cyclosporine, steroids · Novartis · Immunology / Transplantation
  This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection.
• Cyclosporin A,mycophenolate mofetil,Methotrexate · Guangxi Medical University · Immunology
  This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism.
• IST (ATG + CsA) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Immunology / Hematology-Oncology
  IST combines anti-thymocyte globulin (ATG) and cyclosporine A (CsA) to suppress T-cell mediated immune responses and prevent graft rejection or autoimmune destruction.
• Steroid + cyclophosphamide · University Hospital, Rouen · Immunology
  Steroids suppress immune inflammation while cyclophosphamide depletes proliferating immune cells, together inducing immunosuppression and potentially promoting immune tolerance.
• Anti R-IL2 + Cyclosporine · University Hospital, Brest · Immunology / Transplantation
  Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection.
• Anti R-IL2 + Cyclosporine then Everolimus · University Hospital, Brest · Immunology / Transplantation
  This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection.
• ATG + CSA · Swiss Cancer Institute · Immunology
  ATG (antithymocyte globulin) and CSA (cyclosporine A) together provide immunosuppression by depleting T cells and inhibiting T cell activation, respectively.
• Cyclophosphamide and ATG · Haukeland University Hospital · Immunology
  Cyclophosphamide and ATG work together to suppress the immune system by eliminating lymphocytes, allowing immune reconstitution and halting autoimmune disease progression.